A hand-held device that would give early warning of ‘acute events’- and so avoid the hospitalisation of thousands of patients with chronic obstructive pulmonary disease (COPD) - is to go into production ahead of clinical trials. This follows an agreement between medical diagnostics company Glyconics and Spectrolytic, a leading developer of infrared (IR) spectrometers.
Glyconics is a company at the forefront of diagnostic innovation, using infrared spectroscopy to analyse samples for markers of disease across a wide range of conditions.
Address: St John’s Innovation Centre Cowley Road Cambridge
Post Code: CB4 0WS
Country: United Kingdom
Membership Type: Professional Individual and Corporate <5